| Title: |
Can Vitamin D Reduce Glucocorticoid-Induced Adverse Effects in Patients with Giant Cell Arteritis? Results from 1568 Patients in the Spanish ARTESER Registry |
| Authors: |
Ghio, Gastón A.; Domínguez Álvaro, Marta; Hernández Rodríguez, Iñigo; Fernández Fernández, Elisa; Silva Díaz, Maite; Belzunegui, Joaquín M.; Moriano, Clara; Sánchez Martín, Julio; Narváez, Javier; Galíndez Agirregoikoa, Eva; Riveros Frutos, Anne; Ortiz Sanjuán, Francisco; Salman Monte, Tarek C.; Vasques Rocha, Margarida; Iñiguez, Carlota L.; García Dorta, Alicia; Molina Almela, Clara; Alcalde Villar, María; Hernández, José L.; Castañeda, Santos; Blanco, Ricardo; ARTESER Project Collaborative Group |
| Source: |
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
| Publisher Information: |
MDPI AG |
| Publication Year: |
2025 |
| Collection: |
Dipòsit Digital de la Universitat de Barcelona |
| Subject Terms: |
Malalties dels ossos; Vitamina D; Arteritis; Bone diseases; Vitamin D |
| Description: |
Objective: To determine whether oral vitamin D supplementation reduces the risk of glucocorticoid (GC)-associated severe adverse events (SAEs) in patients with giant cell arteritis (GCA) included in the Spanish ARTESER registry. Methods: The ARTESER registry collected data from patients diagnosed with GCA across 26 Spanish public hospitals between June 2013 and March 2019. SAEs were defined as fatal, life-threatening, or requiring hospitalization. Patients were categorized according to the use or non-use of oral vitamin D supplements. Incidence rates (IRs) of SAEs were expressed per person-year with 95% confidence intervals (CIs). Cox proportional hazards models assessed vitamin D supplementation and its interaction with cumulative glucocorticoid dose. Results: Of 1568 patients (mean age 76.9 +/- 8.1 years; 70.1% women) receiving GC, 120 (7.6%) experienced SAEs (IR 0.039; 95% CI 0.033-0.047). Vitamin D supplementation was documented in 1186 (75.6%) compared with 382 (24.4%) non-supplemented patients. SAE incidence was similar in supplemented (n = 89; 7.5%; IR 0.038, 95% CI 0.030-0.046) and non-supplemented patients (n = 31; 8.1%; IR 0.045, 95% CI 0.031-0.064) (p = 0.387). Multivariable Cox regression showed a significant interaction between vitamin D supplementation and cumulative glucocorticoid dose (interaction term HR 0.90; p = 0.033), consistent with a dose-dependent protective effect. Conclusions: Vitamin D supplementation was not independently associated with a lower incidence of GC-related SAEs, likely due to residual confounding factors. However, the interaction with cumulative GC exposure suggests a modulatory effect. Prospective studies incorporating stratified baseline vitamin D assessments are warranted. |
| Document Type: |
article in journal/newspaper |
| File Description: |
11 p.; application/pdf |
| Language: |
English |
| ISSN: |
41156544 |
| Relation: |
Reproducció del document publicat a: https://doi.org/10.3390/nu17203291; Nutrients, 2025, vol. 17, num. 20, 3291; https://doi.org/10.3390/nu17203291; https://hdl.handle.net/2445/224345 |
| Availability: |
https://hdl.handle.net/2445/224345 |
| Rights: |
cc-by (c) Ghio, Gastón A. et al., 2025 ; https://creativecommons.org/licenses/by/4.0/ ; info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.9B25ED8C |
| Database: |
BASE |